CA Clinics Cuts Cannabis Costs for 70% of Australian Patients

The new initiative from Southern Cannabis Holdings —which owns and operates CA Clinics—will slash consultation prices for the 70% of Australians living in metropolitan areas that require medicinal cannabis treatment.

Australia's leading medicinal cannabis clinic network, CA Clinics, announced today that it has radically simplified its pricing model, significantly improving accessibility for Australian patients.

The announcement follows a recent decision by the Australian Government to include the CA Clinics network in its Telehealth initiative, which the company plans on leveraging to allow for more cost-effective and convenient treatment options.

COVID-19 has created a lot of anxiety and financial uncertainty for many patients, so our clinics business has launched this new pricing initiative in order to better meet their needs. Ultimately, paving a path to greater affordability and accessibility to medicinal cannabis as a treatment option is a shared goal of the industry, regulators and advocates alike. Southern Cannabis Holdings CEO, Tim Drury

The company had previously introduced a "telehealth-driven, Medicare Benefits Schedule (MBS) subsidised, specialist model", aimed at regional and rural communities, however this service will now be expanded to patients in metropolitan areas as well.

Additionally, the out-of-pocket costs to patients will now remain uniform, regardless of how long the consultation actually takes.

The key pricing changes being introduced are:

  • Initial Telehealth Consultations—with a full assessment of patient's condition and suitability for treatment—will have the cost reduced to $99.
  • Monitoring Telehealth Consultations to manage a patient's progress will be discounted by nearly 40% to $49.

Concession card holders and Department of Veterans Affairs (DVA) consultations are now also eligible to qualify for bulk billing, although all prospective patients will still require a referral from their GP or a specialist.

"CA Clinics understands that cash flow can be an issue for patients, especially in the time of Covid-19, and so has implemented these pricing changes in order to make medicinal cannabis treatment options more affordable and accessible to those in need," General Manager Andrew Glover said.

The announcement comes just weeks after Applied Cannabis Research—which operates as the research division of Southern Cannabis Holdings—kicked off a new study into the effects of cannabis as a treatment for anxiety disorders.

The decision to pursue the anxiety study was also motivated by a desire to offer further community support during the COVID-19 outbreak, after CA Clinics Medical Advisory Board Member, Dr Mark Hardy, confirmed that there had been a significant increase in patients demonstrating anxiety symptoms since the pandemic began.

"It is imperative for sufferers to have access to the resources and treatment that can best assist them at this time, and Telehealth is certainly an increasingly important and safe avenue to provide this, as it requires no physical contact or travel – essential ingredients while the population is being urged to self-isolate," Dr Hardy said.

"Medicinal cannabis is increasingly being explored as part of GP mental health treatment plans for a range of conditions for which there is some evidence of efficacy including panic disorders, phobias and sleep disturbances."

"It may also provide benefits for more specific forms of anxiety such as PTSD as cannabinoids have been shown to change how the brain processes memories, and studies with Australian veterans suffering from PTSD are ongoing."


This pot stock could reach new heights in 2020 due to Coronavirus

The COVID-19 pandemic is showing no signs of slowing down, and as global markets enter meltdown many cannabis companies are feeling the effects of capital crunch.

While the market crash will continue for some time, it represents a golden opportunity for investors who are capable of riding out the volatility until share prices rally.

Luckily, one pot stock has developed antimicrobial drug that can already treat two superbugs while limiting their ability to develop antibiotic resistance.

Investors can also start picking up shares at rock bottom prices, as global investor sentiment continues to dampen thanks to COVID-19.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Hugo Gray
Hugo Gray

Hugo Gray is a Melbourne-based journalist with a body of work that covers a diverse range of topics, including immigration law, sex technology, and now the rapidly expanding cannabis industry.

Leave a Reply

Your email address will not be published. Required fields are marked *